Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In 1999, the US FDA first approved Pegylated Liposomal Doxorubicin for the treatment of platinum-refractory (recurrent) ovarian cancer following the failure of previous therapies. Later, in 2005, the FDA broadened this approval to include platinum-sensitive recurrent ovarian cancer. This decision was based on data demonstrating that Pegylated liposomal doxorubicin provided improved progression-free survival and was not inferior in terms of overall survival when compared to topotecan (1, 2).
Pegylated liposomal doxorubicin has received [approval from the EMA](brain…